- Home
- MODV vs ACET Comparison
MODV vs ACET Comparison
Compare MODV & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODV
- ACET
- Stock Information
- Founded
- MODV 1996
- ACET 1947
- Country
- MODV United States
- ACET United States
- Employees
- MODV N/A
- ACET N/A
- Industry
- MODV Transportation Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- MODV Consumer Discretionary
- ACET Health Care
- Exchange
- MODV Nasdaq
- ACET Nasdaq
- Market Cap
- MODV 81.8M
- ACET 83.2M
- IPO Year
- MODV N/A
- ACET N/A
- Fundamental
- Price
- MODV $5.05
- ACET $0.98
- Analyst Decision
- MODV Buy
- ACET Buy
- Analyst Count
- MODV 5
- ACET 5
- Target Price
- MODV $18.20
- ACET $5.67
- AVG Volume (30 Days)
- MODV 634.6K
- ACET 1.6M
- Earning Date
- MODV 03-04-2025
- ACET 03-18-2025
- Dividend Yield
- MODV N/A
- ACET N/A
- EPS Growth
- MODV N/A
- ACET N/A
- EPS
- MODV N/A
- ACET N/A
- Revenue
- MODV $2,787,619,000.00
- ACET N/A
- Revenue This Year
- MODV $3.37
- ACET N/A
- Revenue Next Year
- MODV $2.71
- ACET N/A
- P/E Ratio
- MODV N/A
- ACET N/A
- Revenue Growth
- MODV 3.16
- ACET N/A
- 52 Week Low
- MODV $3.64
- ACET $0.81
- 52 Week High
- MODV $39.48
- ACET $2.61
- Technical
- Relative Strength Index (RSI)
- MODV 38.32
- ACET 57.01
- Support Level
- MODV $5.73
- ACET $0.84
- Resistance Level
- MODV $6.09
- ACET $1.04
- Average True Range (ATR)
- MODV 0.60
- ACET 0.08
- MACD
- MODV 0.35
- ACET 0.01
- Stochastic Oscillator
- MODV 54.23
- ACET 68.65
About MODV ModivCare Inc.
ModivCare Inc is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for payors and their members. The company is also a provider of non-emergency medical transportation, or NEMT, personal care, and remote patient monitoring, or RPM, solutions, which serve similar, highly vulnerable patient populations. Its operating segment includes NEMT, Personal Care, and Remote Patient Monitoring. The company generates maximum revenue from the NEMT segment.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.